Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: Global anticoagulant registry in the field - Venous thromboembolism (Garfield-VTE): Rationale and design
Authors: Jeffrey I. Weitz
Sylvia Haas
Walter Ageno
Pantep Angchaisuksiri
Henri Bounameaux
Joern Dalsgaard Nielsen
Samuel Z. Goldhaber
Shinya Goto
Gloria Kayani
Lorenzo Mantovani
Paolo Prandoni
Sebastian Schellong
Alexander G.G. Turpie
Ajay K. Kakkar
Thrombosis & Atherosclerosis Research Institute
Technical University of Munich
Universita degli Studi dell'Insubria
Mahidol University
Hôpitaux universitaires de Genève
Frederiksberg Hospital
Harvard Medical School
Tokai University
Thrombosis Research Institute
University of Milano - Bicocca
Università degli Studi di Padova
Krankenhaus Dresden-Friedrichstadt
McMaster University
Keywords: Medicine
Issue Date: 1-Dec-2016
Citation: Thrombosis and Haemostasis. Vol.116, No.6 (2016), 1172-1179
Abstract: © Schattauer 2016. Venous thromboembolism (VTE) is a common disorder associated with significant rates of morbidity and mortality. VTE management aims to reduce mortality, the risks of recurrence, and long-term complications. VTE treatment is evolving with the introduction of non-vitamin K antagonist anticoagulants (NOACs). The Global Anticoagulant Registry in the FIELD - Venous Thromboembolism (GARFIELD-VTE) is a prospective, multicentre, observational study that will enrol 10,000 patients treated for acute VTE from ~500 sites in 28 countries. Identified sites reflect the diversity of care settings, including hospital and outpatient settings. Patients will be managed according to local practices and followed for at least three years. The primary objective is to determine the extent to which VTE treatment varies in the real-world setting and to assess the impact of such variability on clinical and economic outcomes. Evolving patterns of care will be captured using two sequential cohorts. The GARFIELD-VTE registry will provide insights into the evolving global treatment patterns for VTE, both deep-vein thrombosis and pulmonary embolism. By enrolling patients from diverse care settings, the registry will provide information on adherence to national and international guidelines, identify good practice as well as treatment deficiencies, and relate patient outcomes to clinical management. The incidence of death, recurrent VTE, bleeding, post-thrombotic syndrome and chronic thromboembolic pulmonary hypertension will be documented. By capturing information during and after anticoagulation treatment, the registry will not only define aspects of the natural history of VTE, but also its economic and societal impact at a regional and global level.
ISSN: 03406245
Appears in Collections:Scopus 2016-2017

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.